reported that patients with mutated ATM have a 4.25-fold higher risk of progression on capecitabine plus oxaliplatin than patients with wild-type ATM (15), and concomitant chemoresistance after treatment limits the therapeutic efficacy in CRC patients (75). Here, ATM is linked to colorectal carcinoma.